
pmid: 14400244
Sclerosing retroperitonitis and sclerosing mediastinitis are fibrotic lesions of soft tissue that simulate clinically certain types of malignant neoplasms. The medical history of a patient having either of these diseases is that of a patient having a malignant disorder. Sclerosing retroperitonitis occludes renal outflow, and sclerosing mediastinitis obstructs venous inflow in the thorax. Sclerosing retroperitonitis"' ' ' "'-'"' 33,36.37,39 j i a s |-,een documented 45 times in the American literature; sclerosing mediastinitis' »• "• ' "• 1 ' 2 ' 4 ' 6 has been described less frequently, appearing in foreign as well as in American reports. The importance of distinguishing sclerosing retroperitonitis and sclerosing mediastinitis from malignant disease is obvious. Moreover, there is a distinct impression expressed by our clinical colleagues that these 2 sclerosing disorders are increasing in incidence. I t is the authors' purpose in this paper to discuss the various features of the 2 disorders as observed in 6 patients, and to catalogue examples of the disorders from the literature.
Mediastinitis, Sclerosis, Humans, Disease, Retroperitoneal Space
Mediastinitis, Sclerosis, Humans, Disease, Retroperitoneal Space
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 138 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 0.1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
